PT 112

Drug Profile

PT 112

Alternative Names: PT-112

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ohio University
  • Developer National Cheng Kung University; Phosplatin Therapeutics; Sarah Cannon Research Institute; SciClone Pharmaceuticals; University of Colorado at Colorado Springs; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Phosphoric acid esters; Platinum complexes; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV, Injection)
  • 24 Sep 2017 Phosplatin Therapeutics plans a phase I/II trial for Multiple myeloma(Second-line therapy) in USA (NCT03288480)
  • 09 Sep 2017 Phosplatin Therapeutics collaborates with Pfizer and Merck for PT 112 in combination with avelumab for phase Ib/IIa trial in several indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top